Purpose No randomized trials have been conducted to directly compare radiotherapy (RT)
with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

Radiotherapy remains the foundation of current treatment for patients with locally advanced
squamous cell carcinoma of the head and neck (SCCHN). It has been shown that the …

PURPOSE We performed an open-label randomized controlled phase III study comparing
treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus …

Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …

Background Intensification of chemoradiation for advanced head and neck squamous cell
carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy …

Purpose To investigate the effect of adding concurrent chemotherapy (CT) to cetuximab plus
radiotherapy (RT; CT-cetux-RT) compared with cetuximab plus RT (cetux-RT) in locally …

Importance Cetuximab-based and carboplatin-based chemoradiotherapy (CRT) are often
used for patients with locally advanced head and neck cancer who are ineligible for …

Purpose Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

PURPOSE: To report toxicity data from the first 13 consecutive patients with locally
advanced head and neck squamous cell carcinoma (LAHNSCC), ineligible for cisplatin …